Alpha-synuclein or Tau in Parkinson’s?

The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.

Exploring Perspectives on Trial Design for Parkinson’s: An Update on the Delphi Study

Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.

News Research news

Cure Parkinson’s Research Committee Internship

Cure Parkinson’s is opening a new internship opportunity for young-career researchers to participate in our grant application process by joining our Research Committee.

A new potential biomarker for Parkinson’s

Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.

Our first pipeline project of research

Our first project from our Research Pipeline Acceleration Programme is now underway. Professor Michael Schwarzchild is investigating evidence needed to determine if three iLCT-evaluated compounds are ready to progress into clinical trials for people with Parkinson’s.